Type 1 diabetes patients require multiple doses of insulin in a day. Advancements in research and technology has led to commercialization of easy-to-use insulin delivery systems such as insulin pens, pumps, inhaled insulin, and injectors. Use of syringes to deliver insulin has become obsolete with the introduction of advanced and easy-to-use insulin delivery systems.
Moreover, these systems offer self-administration of insulin. Artificial pancreas system automatically detects glucose level in patient’s blood or plasma, and accordingly administers necessary dosage of insulin. For instance, Medtronic's MiniMed 670G is one such wearable artificial pancreas that automatically monitors glucose levels, and delivers insulin through an insulin pump attached to the device. The artificial pancreas technology includes a transmitter, sensor, and insulin pump. This helps in continuous monitoring of insulin levels in body and manages diabetes at ease.
Market Dynamics
Continuous research and development of novel artificial pancreas device systems is expected to support the artificial pancreas device system (APDS) market growth over the forecast period.
For instance, in May 2019, Beta Bionics, Inc. and Zealand Pharma started an in-home trial of iLet Bionic Pancreas system, a dual-hormone pump system designed to automatically deliver insulin and dasiglucagon – an experimental form of glucagon designed by Zealand Pharma to be stable in liquid form- based on blood sugar readings from a continuous glucose monitor (CGM).
High prevalence of diabetes type 1 is expected to rise demand for its novel monitoring systems and drive the artificial pancreas device system (APDS) market growth over the forecast period.
For instance, according to the World Health Organization (WHO), number of diabetes patients worldwide increased from 108 million in 1980 to 422 million in 2014. Furthermore, according to the Center for Disease Control and Prevention (CDC), type 1 diabetes accounts for around 5% of the total diagnosed diabetes cases in adults in the U.S.
Key features of the study:
- This report provides in-depth analysis of global artificial pancreas device system (APDS) market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2020 – 2027), considering 2019, as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, regional outlook, and competitive strategy adopted by leading players
- It profiles leading players in the global artificial pancreas device system (APDS) market based on following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies, and future plans
- Key companies covered as a part of this study include Medtronic Plc., Medtrum Technologies Inc., Tandem Diabetes Care, Inc., Johnson & Johnson, Beta Bionics, Inc., Bigfoot Biomedical, Insulet Corporation, Pancreum, Inc., TypeZero Technologies, Inc., DreaMed Diabetes Ltd, and Inreda Diabetic BV
- Insights from this report would allow marketers and management authorities of companies to make informed decisions regarding future product launches, technology up-gradation, market expansion, and marketing tactics
- The global artificial pancreas device system (APDS) market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through the various strategy matrices used in analyzing the global artificial pancreas device system (APDS) market
Detailed Segmentation:
- Global Artificial Pancreas Device System (APDS) Market, By Technology :
- Threshold Suspended Device Systems
- Treat to Range/Control to Range (TTR/CTR)
- Treat to Target/ Control to Target (TTR/CTT)
- Global Artificial Pancreas Device System (APDS) Market, By Distribution Channel:
- Hospital & Clinics
- Retail Channels
- Online Channels
- Global Artificial Pancreas Device System (APDS) Market, By Region:
- North America
- By Technology :
- Threshold Suspended Device Systems
- Treat to Range/Control to Range (TTR/CTR)
- Treat to Target/ Control to Target (TTR/CTT)
- By Distribution Channel:
- Hospital & Clinics
- Retail Channels
- Online Channels
- By Country:
- Europe
- By Technology :
- Threshold Suspended Device Systems
- Treat to Range/Control to Range (TTR/CTR)
- Treat to Target/ Control to Target (TTR/CTT)
- By Distribution Channel:
- Hospital & Clinics
- Retail Channels
- Online Channels
- By Country:
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- By Technology :
- Threshold Suspended Device Systems
- Treat to Range/Control to Range (TTR/CTR)
- Treat to Target/ Control to Target (TTR/CTT)
- By Distribution Channel:
- Hospital & Clinics
- Retail Channels
- Online Channels
- By Country:
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- By Technology :
- Threshold Suspended Device Systems
- Treat to Range/Control to Range (TTR/CTR)
- Treat to Target/ Control to Target (TTR/CTT)
- By Distribution Channel:
- Hospital & Clinics
- Retail Channels
- Online Channels
- By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Middle East
- By Technology :
- Threshold Suspended Device Systems
- Treat to Range/Control to Range (TTR/CTR)
- Treat to Target/ Control to Target (TTR/CTT)
- By Distribution Channel:
- Hospital & Clinics
- Retail Channels
- Online Channels
- By Country:
- GCC
- Israel
- Rest of Middle East
- Africa
- By Technology :
- Threshold Suspended Device Systems
- Treat to Range/Control to Range (TTR/CTR)
- Treat to Target/ Control to Target (TTR/CTT)
- By Distribution Channel:
- Hospital & Clinics
- Retail Channels
- Online Channels
- By Country/Region:
- Central Africa
- South Africa
- North Africa
- Company Profiles
- Medtronic Plc.*
- Company Overview
- Product Portfolio
- Financial Performance
- Key Strategies
- Recent Developments
- Medtrum Technologies Inc.
- Tandem Diabetes Care, Inc.
- Johnson & Johnson
- Beta Bionics, Inc.
- Bigfoot Biomedical
- Insulet Corporation
- Pancreum, Inc.
- TypeZero Technologies, Inc.
- DreaMed Diabetes Ltd
- Inreda Diabetic BV
“*” marked represents similar segmentation in other categories in the respective section.
